Immuno-Oncology | Specialty

Combination of Immunotherapy and Lung Cancer Therapies Potential Game-Changer, But Needs Further Research

August 9th 2016

Paul A. Bunn Jr, MD, discussed how combining immunotherapy with chemotherapy, molecular therapy, or anti-angiogenic therapy has shown promising results in recent randomized trials of patients with lung cancer, although the combinations have yet to demonstrate clear superiority.

CheckMate-026 Underscores Predictive Value of High PD-L1 Expression

August 9th 2016

The value of PD-L1 expression when using checkpoint inhibitors in non–small cell lung cancer is underscored by the just-announced disappointing progression-free survival findings from the phase III CheckMate-026 study of frontline nivolumab (Opdivo) versus physician's choice of combination chemotherapy.

Weber Discusses Sequential Versus Concurrent Immunotherapy in Melanoma

August 9th 2016

Jeffery S. Weber, MD, PhD, discusses findings from the phase II CheckMate-064 trial, in which patients were randomized to receive either nivolumab followed by ipilimumab followed by nivolumab maintenance therapy, or ipilimumab followed by nivolumab and maintenance therapy with nivolumab.

FDA Approves Pembrolizumab for Head and Neck Cancer

August 6th 2016

The FDA has granted an accelerated approval to pembrolizumab as a treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma following progression on a platinum-based chemotherapy.

Dr. Ferris on FDA Approval of Pembrolizumab in Head and Neck Cancer

August 6th 2016

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and coleader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses the impact of the FDA approval of pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.

Dr. Bunn on Missed Endpoint for Nivolumab in CheckMate-026 for NSCLC

August 5th 2016

Paul A. Bunn Jr, MD, Distinguished Professor, Division of Medical Oncology/University of Colorado, James Dudley Chair in Lung Cancer Research, University of Colorado Denver, 2014 Giant of Cancer Care in Lung Cancer, discusses the phase III results from CheckMate-026, which explored nivolumab (Opdivo) monotherapy in treatment-naïve patients with advanced non–small cell lung cancer.

Dr. David F. McDermott on Nivolumab in RCC

August 5th 2016

Nivolumab Misses PFS Endpoint in Frontline Phase III NSCLC Study

August 5th 2016

Monotherapy with nivolumab failed to improve progression-free survival compared with physician's choice of combination chemotherapy for patients with PD-L1–positive non–small cell lung cancer.

Dr. Garon on Immunotherapy for Patients With NSCLC

August 5th 2016

Edward B Garon, MD, director, Thoracic Oncology, Jonnson Comprehensive Cancer Center, UCLA, discusses the evolution of immunotherapy for the treatment of patients with non–small cell lung cancer.

New Immunotherapy Classes Emerge in Lung Cancer

August 4th 2016

New classes of immunotherapies emerging in lung cancer are building on previous success with PD-1/PD-L1 inhibitors.

New Checkpoint Target Emerges in Bladder Cancer

August 4th 2016

Alexander I. Sankin, MD, discusses how bladder cancer researchers are looking beyond PD-L1 and CTLA-4 to HHLA2, a potentially druggable new checkpoint target.

Pembrolizumab Gains European Approval for PD-L1+ NSCLC

August 3rd 2016

The European Commission has approved pembrolizumab (Keytruda) as a treatment for patients with locally advanced or metastatic PD-L1–positive non–small cell lung cancer following at least 1 chemotherapy regimen.

Dr. Peter O'Donnell on Atezolizumab and IMvigor 210

August 2nd 2016

Testing the Immune Memory: How Much Anti-PD-1/PD-L1 Therapy Is Enough?

August 2nd 2016

There is some evidence that relatively short treatment courses might also be appropriate for other checkpoint inhibitors approved for treating some cancers, but the data are fairly sparse.

Dr. Topalian on Evolution of PD-1/PD-L1 Agents in Oncology

August 1st 2016

Suzanne L. Topalian, MD, director, Melanoma Program, professor of Surgery, Johns Hopkins Medicine, discusses how the use of PD-1/PD-L1 inhibitors in multiple tumor types has dramatically evolved over the last 4 years.

Dr. Arkenau on Advancements on Horizon in Gastric Cancer

July 27th 2016

Hendrik-Tobias Arkenau, MD, PhD, founding medical director, executive medical director, Sarah Cannon Research Institute UK, discusses immunotherapy advancements on the horizon in the field of gastric cancer.

The Future of Myeloma Research

July 27th 2016

Relapse Type and Monoclonal Antibody Choice in Multiple Myeloma

July 27th 2016

Sequencing Monoclonal Antibodies in Myeloma

July 27th 2016

Moving Beyond Medians

July 27th 2016